Warfarin Genetic Test Not Cost Effective for Initial Dosing | GenomeWeb

NEW YORK (GenomeWeb News) – Genetic testing for initial warfarin dosing is not cost effective for most patients, according to research appearing online today in the Annals of Internal Medicine. Instead, the study suggested, such tests may be more suitable for those at high risk of hemorrhaging.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.